Neuphoria Therapeutics Inc. (NEUP)
Oxford Ledge is still expanding full research coverage of NEUP. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Neuphoria develops neuropsychiatric therapies, with BNC210 advancing in Phase 3 trials for anxiety and PTSD, plus partnerships with Merck and Carina Biotech.
SEC filings
- 8-K Other material event 2026-05-26
- 10-Q Quarterly financial report (unaudited) 2026-05-15
- 10-Q Quarterly financial report (unaudited) 2026-02-17
- 8-K Entry into material agreement; Termination of material agreement; Financial statements and exhibits 2026-01-08
- 8-K Delisting / transfer of listing 2025-12-18
Source: SEC EDGAR.
Annual results
3 years of annual figures for NEUP, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | $15.6M | -$369,632 | -$0.23 |
| 2024 | — | -$15.5M | -$18.62 |
| 2023 | — | -$21.4M | -$0.02 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for NEUP. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open NEUP in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.